ImmunoGen presents data from FORWARD II Triplet Cohort at ESMO
Category: #health  By Mateen Dalal  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

ImmunoGen presents data from FORWARD II Triplet Cohort at ESMO

Ovarian cancer occurs when cells in the ovary start to mutate abnormally, further forming a tumor. At late stages, ovarian cancer can become difficult to treat and could also be fatal to patient. Several pharmaceutical firms are focusing on developing an effective drug via means of advanced clinical trials and research.

One such development was made by ImmunoGen, Inc., a leading biotech company that develops novel treatments for cancer. The firm recently announced data indicating overall response and initial safety of mirvetuximab in a Phase 1b FORWARD II triplet cohort when it was combined with Avastin® (bevacizumab) and carboplatin in patients with recurring, platinum-sensitive ovarian cancer.

Reportedly, the data was presented at the ESMO (European Society for Medical Oncology) 2019 Congress held in Spain. According to David O'Malley, M.D., Principal Investigator of FORWARD II, the primary results of mirvetuximab paired with both carboplatin and bevacizumab demonstrated promising data, when compared with earlier results when mirvetuximab was combined with these drugs individually.

O’Malley claims that the anti-tumor responses are way better than the other triplets that are currently being tested. Furthermore, he hopes to establish longer-term efficiency data, as the company seeks to offer latest treatment opportunities for patients suffering from ovarian cancer.

Anna Berkenblit, M.D., Vice President and Chief Medical Officer, ImmunoGen, said that the company is delighted with the overall response and initial safety data from the triplet cohort of mirvetuximab and is looking forward to recording strong results from its studies.

She added that their firm is constantly following patients for progression-free survival and hopes to commence its future studies, in order to pave the way for its registration in ovarian cancer.

Incidentally, ImmunoGen had also made headlines when it revealed that the United States Food and Drug Administration (FDA) had suggested it to initiate a new Phase 3 randomized trial to assess the efficacy and safety of mirvetuximab soravtansine in patients with high FRα (folate receptor alpha) +ve, platinum-resistant ovarian cancer.

Source Credit: http://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-initial-data-phase-1b-forward-ii-triplet

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Cryptocurrency platform Binance acquires dApp startup DappReview
Cryptocurrency platform Binance acquires dApp startup DappReview
By Mateen Dalal

Binance, a renowned cryptocurrency exchange platform where more than 100 cryptocurrencies are traded, reportedly announced the acquisition of DappReview, an evaluation platform offering advertising and data-driven research services to blockchain-base...

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
By Mateen Dalal

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Ap...

Prescient expands PTX-200 trial after it eradicates cancer completely
Prescient expands PTX-200 trial after it eradicates cancer completely
By Mateen Dalal

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemia) after the disease was complet...